User login
Key clinical point: Adjuvant celecoxib for 2 years vs placebo fails to extend survival in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Major finding: In patients who received celecoxib vs placebo, no significant difference was observed in the disease-free survival (P = 0.75) and the overall survival (P = 0.78). In the celecoxib vs. placebo group, similar rates of cardiac events (15% vs. 13%) and new primary non-breast cancers (4% vs 4%) were reported.
Study details: A phase 3, randomized, double-blind study of patients with HER2-negative breast cancer who were randomly assigned to adjuvant celecoxib for 2 years or placebo following complete resection.
Disclosures: The study was supported by Pfizer, Cancer Research UK, The Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research, London. The authors reported receiving grants, research funding, personal fees, advisory fees, nonfinancial support, and/or honoraria and/or having patents outside this work.
Source: Coombes RC et al. JAMA Oncol. 2021 Jul 15 (in press). doi: 10.1001/jamaoncol.2021.2193.
Key clinical point: Adjuvant celecoxib for 2 years vs placebo fails to extend survival in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Major finding: In patients who received celecoxib vs placebo, no significant difference was observed in the disease-free survival (P = 0.75) and the overall survival (P = 0.78). In the celecoxib vs. placebo group, similar rates of cardiac events (15% vs. 13%) and new primary non-breast cancers (4% vs 4%) were reported.
Study details: A phase 3, randomized, double-blind study of patients with HER2-negative breast cancer who were randomly assigned to adjuvant celecoxib for 2 years or placebo following complete resection.
Disclosures: The study was supported by Pfizer, Cancer Research UK, The Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research, London. The authors reported receiving grants, research funding, personal fees, advisory fees, nonfinancial support, and/or honoraria and/or having patents outside this work.
Source: Coombes RC et al. JAMA Oncol. 2021 Jul 15 (in press). doi: 10.1001/jamaoncol.2021.2193.
Key clinical point: Adjuvant celecoxib for 2 years vs placebo fails to extend survival in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Major finding: In patients who received celecoxib vs placebo, no significant difference was observed in the disease-free survival (P = 0.75) and the overall survival (P = 0.78). In the celecoxib vs. placebo group, similar rates of cardiac events (15% vs. 13%) and new primary non-breast cancers (4% vs 4%) were reported.
Study details: A phase 3, randomized, double-blind study of patients with HER2-negative breast cancer who were randomly assigned to adjuvant celecoxib for 2 years or placebo following complete resection.
Disclosures: The study was supported by Pfizer, Cancer Research UK, The Royal Marsden NHS Foundation Trust, and the Institute of Cancer Research, London. The authors reported receiving grants, research funding, personal fees, advisory fees, nonfinancial support, and/or honoraria and/or having patents outside this work.
Source: Coombes RC et al. JAMA Oncol. 2021 Jul 15 (in press). doi: 10.1001/jamaoncol.2021.2193.